Literature DB >> 20692295

Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan.

Junko Hattori1, Teiichiro Shiino, Hiroyuki Gatanaga, Shigeru Yoshida, Dai Watanabe, Rumi Minami, Kenji Sadamasu, Makiko Kondo, Haruyo Mori, Mikio Ueda, Masao Tateyama, Atsuhisa Ueda, Shingo Kato, Toshihiro Ito, Masayasu Oie, Noboru Takata, Tsunefusa Hayashida, Mami Nagashima, Masakazu Matsuda, Shiro Ibe, Yasuo Ota, Satoru Sasaki, Yoshiaki Ishigatsubo, Yoshinari Tanabe, Ichiro Koga, Yoko Kojima, Masahiro Yamamoto, Jiro Fujita, Yoshiyuki Yokomaku, Takao Koike, Takuma Shirasaka, Shinichi Oka, Wataru Sugiura.   

Abstract

The emergence and transmission of drug-resistant human immunodeficiency virus-1 (HIV-1) compromises antiretroviral treatment for HIV-1. Thus, testing for drug resistance is recommended at diagnosis and before initiating highly active antiretroviral treatment. We conducted an epidemiological study enrolling newly diagnosed patients between 2003 and 2008 in our nationwide surveillance network. In the 6-year study period, the prevalence of drug-resistant HIV-1 among 2573 patients, consisting mainly of Japanese men in their late-30s and infected through male-to-male sexual contacts, followed an increasing trend from 5.9% (16/273) in 2003 to 8.3% (50/605) in 2008. Nucleoside reverse transcriptase inhibitor-associated mutations predominated in each year, with T215 revertants being the most abundant. The predictive factor for drug-resistant HIV-1 transmission was subtype B (OR=2.36; p=0.004), and those for recent HIV-1 infection were male gender (OR=3.79; p=0.009), MSM behavior (OR=1.67; p=0.01), Japanese nationality (OR=2.31; p=0.008), and subtype B (OR=5.64; p<0.05). Continued activities are needed to raise awareness of the risks of HIV-1 infection and complications of drug-resistant strains. Continued surveillance is also needed to understand trends in the HIV-1 epidemic.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20692295     DOI: 10.1016/j.antiviral.2010.07.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  24 in total

1.  HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan.

Authors:  Masumi Hosaka; Seiichiro Fujisaki; Aki Masakane; Junko Hattori; Teiichiro Shiino; Hiroyuki Gatanaga; Urara Shigemi; Reiko Okazaki; Atsuko Hachiya; Masakazu Matsuda; Shiro Ibe; Yasumasa Iwatani; Yoshiyuki Yokomaku; Wataru Sugiura
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11-16       Impact factor: 2.205

2.  Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material.

Authors:  Shigeru Yoshida; Junko Hattori; Masakazu Matsuda; Kiyomi Okada; Yukumasa Kazuyama; Osamu Hashimoto; Shiro Ibe; Shin-ichi Fujisawa; Hitoshi Chiba; Masashi Tatsumi; Shingo Kato; Wataru Sugiura
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12-03       Impact factor: 2.205

3.  Transmitted antiretroviral drug resistance and thumb subdomain polymorphisms among newly HIV type 1 diagnosed patients infected with CRF01_AE and CRF07_BC virus in Guangdong Province, China.

Authors:  Changfu Yang; Shuyuan Liu; Taisong Zhang; Yaping Hou; Xiaoli Liu; Yun Gao; Guang Yang; Zhen Wang; Huayun Chen; Ming Li; Zhenyu Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-12       Impact factor: 2.205

4.  Phylodynamic analysis of a viral infection network.

Authors:  Teiichiro Shiino
Journal:  Front Microbiol       Date:  2012-07-31       Impact factor: 5.640

Review 5.  HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Authors:  Michele W Tang; Robert W Shafer
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

6.  National prevalence and trends of HIV transmitted drug resistance in Mexico.

Authors:  Santiago Avila-Ríos; Claudia García-Morales; Daniela Garrido-Rodríguez; Christopher E Ormsby; Ramón Hernández-Juan; Jaime Andrade-Villanueva; Luz A González-Hernández; Indiana Torres-Escobar; Samuel Navarro-Álvarez; Gustavo Reyes-Terán
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

7.  Chemokine co-receptor usage in HIV-1-infected treatment-naïve voluntary counselling and testing clients in Southern Taiwan.

Authors:  Hung-Chin Tsai; Pei-Yun Chou; Shue-Ren Wann; Susan Shin-Jung Lee; Yao-Shen Chen
Journal:  BMJ Open       Date:  2015-04-29       Impact factor: 2.692

8.  Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.

Authors:  Masako Nishizawa; Junko Hattori; Teiichiro Shiino; Tetsuro Matano; Walid Heneine; Jeffrey A Johnson; Wataru Sugiura
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

9.  Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.

Authors:  Masako Nishizawa; Masakazu Matsuda; Junko Hattori; Teiichiro Shiino; Tetsuro Matano; Walid Heneine; Jeffrey A Johnson; Wataru Sugiura
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

10.  Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk.

Authors:  Mayumi Imahashi; Taisuke Izumi; Dai Watanabe; Junji Imamura; Kazuhiro Matsuoka; Hirotaka Ode; Takashi Masaoka; Kei Sato; Noriyo Kaneko; Seiichi Ichikawa; Yoshio Koyanagi; Akifumi Takaori-Kondo; Makoto Utsumi; Yoshiyuki Yokomaku; Takuma Shirasaka; Wataru Sugiura; Yasumasa Iwatani; Tomoki Naoe
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.